高盛发声:中国创新药价值重估时代来临

格隆汇
17 Jul

格隆汇7月17日|据药研网,高盛发布的研报直言:中国Biotech板块正进入结构性重估窗口期。当前中国生物技术公司整体市值仅为美国同行的14%-15%,但其在全球创新贡献中的比重已接近33%。这意味着,中国创新药板块仍处于‘价值洼地’阶段,全球资本重估才刚刚开始。”

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10